Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport

Kidney International

Volumn 73, Issue SUPPL. 108, 2008, Pages

  Del Peso, G ^a   Jimenez Heffernan J A ^b   Bajo, M A ^a   Aroeira, L S ^a   Aguilera, A ^c   Fernandez Perpen A ^c   Cirugeda, A ^c   Castro, M J ^a   De Gracia, R ^a   Sanchez Villanueva R ^a   Sanchez Tomero J A ^c   Lopez Cabrera M ^c   Selgas, R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Epithelial to mesenchymal transition; Mesothelial cell; Peritoneal biopsy; Peritoneal high transport; Submesothelial fibrosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYTOKERATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MESENCHYME CELL; MESOTHELIUM CELL; MYOFIBROBLAST; PERITONEAL BIOPSY; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; ULTRAFILTRATION; VASCULAR DISEASE; BIOPSY; CELL DIFFERENTIATION; EPITHELIUM; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PERITONEUM; PHENOTYPE; PHYSIOLOGY; REGRESSION ANALYSIS; TIME; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ADULT; AGED; BIOLOGICAL TRANSPORT; BIOPSY; CELL DIFFERENTIATION; CREATININE; EPITHELIAL CELLS; EPITHELIUM; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEAL DIALYSIS; PERITONEUM; PHENOTYPE; REGRESSION ANALYSIS; TIME FACTORS;

EID: 44449167771     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002598     Document Type: Article

References (46)

1. Gokal R, Khanna R, Krediet R, Nolph K (eds). The Textbook of Peritoneal Dialysis, 2nd edn. Kluwer Academic Publishers: Dordrecht, 2000, 862pp.
2. De Vriese AS, Mortier S, Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Dial Int 2001; 21(Suppl 3): S9-S18.
3. Selgas R, Fernández-Reyes MJ, Bosque E et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 1994; 23: 64-73.
4. Selgas R, Bajo MA, Del Peso G et al. Preserving the peritoneal dialysis membrane in long-term peritoneal dialysis patients. Semin Dial 1995; 8: 326-332.
5. Selgas R, Bajo MA, Paiva A et al. Stability of the peritoneal membrane in long-term peritoneal dialysis patients. Adv Ren Replace Ther 1998; 5: 168-178.
6. Krediet R. The peritoneal membrane in chronic peritoneal dialysis patients. Kidney Int 1999; 55: 341-356.
7. Smit W, Van Dijk P, Lagedijk MJ et al. Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003; 23: 440-449.
8. Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13: 962-968.
9. Churchill DN, Thorpe KE, Nolph KD, et al., for CANUSA Study group. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 1285-1292.
10. Díaz-Buxo JA, Lowrie EG, Lew NL et al. Associates of mortality among peritoneal dialysis patients with special references to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33: 523-534.
11. Ates K, Nergizoglu K, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776.
12. Garosi G, Di Paolo N. Peritoneal sclerosis - an overview. Adv Perit Dial 1999; 15: 185-192.
13. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4): S22-S42.
14. Combet S, Miyata T, Moulin P et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000; 11: 717-728.
15. Selgas R, Del Peso G, Bajo MA et al. Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis. Perit Dial Int 2000; 20: 798-801.
16. Selgas R, del Peso G, Bajo MA et al. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent. J Nephrol 2001; 14: 270-274.
17. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-541.
18. De Vriese AS, Tilton RG, Mortier S et al. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21: 2549-2555.
19. Yáñrez-Mó M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis induces an epithelial-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413.
20. Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int 2003; 63: 1530-1539.
21. Mateijsen MAM, van der Wal AC, Hendriks PMEM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525.
22. Plum J, Hermann S, Fussholler A et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int 2001; 78(Suppl): S424-S427.
23. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
24. Bertoli SV, Buzzi L, Ciurlino D. Morphofunctional study of peritoneum in peritoneal dialysis patients. J Nephrol 2003; 16: 373-378.
25. Krediet RT, Zweers MM, van der Wal AC et al. Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000; 20(Suppl 2): S19-S25.
26. Jiménez-Heffernan JA, Aguilera A, Aroeira LS et al. Immunohistochemical characterization of fibroblast subpopulation in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchow Arch Pathol Anat Physiol Klin Med 2004; 444: 247-256.
27. Bucala R, Spiegel LA, Chesney J et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
28. Del Peso G, Jiménez-Heffernan JA, Bajo MA et al. Myofibroblastic differentiation in simple peritoneal sclerosis. Int J Artif Organs 2005; 28: 135-140.
29. Powell DW, Mifflin RC, Valentich JD et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277: C1-C9.
30. Numata M, Nakayama M, Nimura S et al. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-122.
31. Sherif AM, Nakayama M, Maruyama Y et al. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant 2006; 21: 1675-1678.
32. Margetts P, Kolb M, Galt T et al. Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12: 2029-2039.
33. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16: 425-436.
34. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
35. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
36. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
37. De Vriese AS, Tilton RG, Stephan CC et al. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12: 1734-1741.
38. Mandl-Weber S, Cohen CD, Haslinger B et al. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61: 570-578.
39. Rodrigues A, Martins M, Santos MJ et al. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport. Adv Perit Dial 2004; 20: 8-12.
40. Aroeira LS, Aguilera A, Selgas R et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46: 938-948.
41. Jiménez-Heffernan JA, Del Peso G, Bajo MA et al. Peritoneal inflammation and fibrosis in peritoneal dialysis. In: Esbrit P, Alvarez-Arroyo MV (eds). Inflammation and Chronic Disease. Transworld Research Network: Kerala, 2006, pp 89-102.
42. Pecoits-Filho R, Araujo MR, Lindholm B et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480-1486.
43. Zweers MM, de Waart DR, Smit W et al. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999; 134: 124-132.
44. Flessner M, Choi J, Vanpelt H et al. Correlating structure with solute and water transport in a chronic model of peritoneal inflammation. Am J Physiol Renal Physiol 2006; 290: F232-F240.
45. Sjøland JA, Pedersen RS, Jespersen J et al. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19: 1264-1268.
46. Honda K, Nitta K, Horita S et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549.